期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

两种不同方法在检测IHC2+的乳腺癌中HER-2/neu基因表达差异的比较研究

Comparison of Two Different Methods in Evaluating the Status of HER-2/neu in Breast Carcinomas Scored IHC2+
下载PDF
导出
摘要 目的探讨免疫组化(immunohistochemistry,IHC)与荧光原位杂交(fluorescence in situ hybridization,FISH)两种技术在检测乳腺浸润性导管癌HER-2/neu为2+时的一致性。方法收集乳腺浸润性导管癌并经IHC证实为2+的标本66例,同时进行FISH检测,比较两者结果的相关性。结果 FISH检测发现在66例IHC为2+的病例中,HER-2/neu基因的阳性率为28.8%(19/66);ER-PR-乳腺癌HER-2/neu基因的阳性率(47.4%)明显高于ER+PR+乳腺癌HER-2/neu基因的阳性率(17.5%),两者具有显著性差异(P<0.05)。结论 IHC证实HER-2/neu为2+时必须进行FISH检测。 Objective To investigate the concordance between immunohistochemistry （IHC） and fluorescence in situ hybridization （FISH） when applied for testing the HER -2/neu status in breast infiltrating ducta] carcinomas scored IHC （2 ＋ ）. Methods Totally 66 cases of breast infiltrating ductal carcinoma scored IHC （2 ＋ ） were collected. For all the cases, the amplification of HER -2/neu was al- so detected by FISH. The results from the two methods were analyzed. Results Of the 66 cases, the positive rate of HER - 2/neu gene amplification was 28.8% （19/66）. The positive rate of HER -2/neu gene amplification in ER -PR - cases （47.4%） was significantly higher than that in ER ＋ PR ＋ cases（ 17.5% ） （ P 〈 0.05 ）. Conclusion It is definitely necessary to do the FISH test of HER - 2/neu in breast carcinomas which are scored 2 ＋ by IHC.
作者 郑炜华 卢洪胜 陈敏芬
机构地区 浙江省临海市第一人民医院妇产科 浙江省台州医院病理科 浙江省台州医院耳鼻喉科
出处 《医学研究杂志》 2013年第10期103-106,共4页 Journal of Medical Research
关键词 乳腺肿瘤 荧光原位杂交HER-2 NEU 免疫组化 Breast cancer FISH HER-2/neu IHC
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献13

  • 1Van de Vijver MJ. Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor - 2 (HER2) [J]. Euro J Cancer, 2001, 37(Supplyl): S11-S17.
  • 2Hynes NE, Stem DF. The biology of erbB - 2/neu/HER - 2 and its role in cancer[J]. Biochem BiophysActa, 1994, 1198(2 -3): 165 - 184.
  • 3Susanne H, Heidrun G, Sylvia R, et al. Expression of heregulin,phosphorylated HER- 2, HER -3 and HER -4 in HER- 2 negative breast cancers [ J ]. Institute of Pathology, 2009,21 (2) : 299 - 304.
  • 4Mrozkowiak A, Olszewski WP, Piascik A, et al. HER2 status in breast cancer determined by IHC and FISH : comparison of the results [J]. Pol J Pathol,2004,55(4) :165 -171.
  • 5Kuo SJ, Wang BB, Chang CS, et al. Comparison of immunohisto- chemical and fluorescence in situ hybridization assessment for HER - 2/neu status in Taiwan Residents breast cancer patients[ J]. Taiwan J Obstet Gynecol, 2007,46(2) :146 - 151.
  • 6Adv Y, Camila A, JairB, et al. Breast cancer HER2 equivocal cases : is there an alternative to FISH testing? A pilot study using two differ- ent antibodies sequentially [ J ]. Israel Med Assoc J, 2010,12 ( 6 ) : 353 -356.
  • 7乳腺癌HER2检测指南（2009版）[J].中华病理学杂志,2009,38(12):836-840. 被引量：193
  • 8Lissandra DL, Virginie D, Christine D, et al. Correction for chromo- some - 17 is critical for the determination of true Her - 2/neu gene amplification status in breast cancer [ J ]. Mol Cancer Ther, 2006,5 (10) :2572 -2579.
  • 9Yaziji H, Goldstein LC, Barry TS, et al. HER -2 testing in breastcancer using parallel tissue - based methods [ J 1 [ J Am Med Assoc, 2004, 291(16) :1972 - 1977.
  • 10Hammock L, Lewis M, Phillips C, et al. Strong HER -2/neu protein overexpressinn by immunohistochemistry often does not predict onco- gene amplification by fluorescence in situ hybridization [ J ]. Hum Pathol,2003,34 (10) : 1043 - 1047.

二级参考文献14

  • 1<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量：164
  • 2Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol, 2007,25 ( 33 ) : 5287-5312.
  • 3Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol,2007,25( 1 ) :118-145.
  • 4Hanna WM, Kwok K. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod Pathol,2006,19(4) :481-487.
  • 5Gong Y, Sweet W, Duh YJ, et al. Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations. Am J Clin Pathol,2009,131 (4) :490-497.
  • 6Dietel M, Ellis IO, Hofler H, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch ,2007,451 ( 1 ) : 19-25.
  • 7Pedersen M, Rasmussen BB. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer. Diagn Mol Pathol,2009,18 (2) :96-102.
  • 8Yaziji H, Gown AM. Accuracy and precision in HER2/neu testing in breast cancer: are we there yet? Hum Pathol, 2004, 35 (2): 143-146.
  • 9Sauter G, Lee J, Bartlett JM, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologie considerations. J Clin Oncol, 2009,27 (8) : 1323- 1333.
  • 10Rhodes A, Jasani B, Anderson E, et al. Evaluation of HER-2/ neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol,2002,118 (3) :408-417.

共引文献192

医学研究杂志
2013年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部